Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation

Background/Aim: Poly (ADP-ribose) polymerase inhibitors (PARPis) are one of the targeted therapies proven to treat breast cancer gene (BRCA)-mutant ovarian cancer. Because most cancers BRCA wild-type, it is necessary extend usage PARPis. In present study, we combined PARPi, talazoparib, and IL-6 inhibitor, bazedoxifene, for treatment human cells. Materials Methods: The cell lines, SKOV3, UWB1.289 (BRCA1-null) OV75, were treated with talazoparib as monotherapy or combination treatment. effects on viability, migration, growth colony formation examined. Western blot was used investigate pathways that may be involved in antitumor two agents. Results: bazedoxifene showed synergistic inhibition growth, all studied lines. expression p-AKT, c-myc, p-ERK, ER? inhibited, ?-H2AX induced. Conclusion: Combined PARP an efficacious cancer, independently mutation status.